UBS Group Issues Pessimistic Forecast for Cabot (NYSE:CBT) Stock Price

Cabot (NYSE:CBT) had its target price cut by research analysts at UBS Group from $93.00 to $83.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “neutral” rating on the specialty chemicals company’s stock. UBS Group’s target price indicates a potential upside of 11.13% from the stock’s previous close.

Several other analysts also recently issued reports on the stock. JPMorgan Chase & Co. cut their target price on shares of Cabot from $105.00 to $85.00 and set an “underweight” rating on the stock in a research note on Friday, February 21st. Mizuho dropped their price target on Cabot from $122.00 to $110.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. Finally, StockNews.com raised Cabot from a “hold” rating to a “buy” rating in a research note on Tuesday, April 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Cabot currently has a consensus rating of “Hold” and a consensus target price of $93.25.

Cabot Trading Down 2.3 %

Shares of NYSE CBT opened at $74.69 on Monday. The company has a quick ratio of 1.29, a current ratio of 2.00 and a debt-to-equity ratio of 0.72. Cabot has a 12 month low of $73.63 and a 12 month high of $117.46. The company has a market cap of $4.05 billion, a price-to-earnings ratio of 9.92, a P/E/G ratio of 0.74 and a beta of 1.04. The business has a fifty day simple moving average of $84.10 and a 200-day simple moving average of $96.66.

Cabot (NYSE:CBT) last posted its quarterly earnings data on Monday, February 3rd. The specialty chemicals company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.74 by $0.02. Cabot had a return on equity of 26.79% and a net margin of 10.60%. Sell-side analysts predict that Cabot will post 7.57 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. R Squared Ltd acquired a new stake in shares of Cabot during the 4th quarter valued at about $26,000. EverSource Wealth Advisors LLC raised its position in Cabot by 37.2% during the fourth quarter. EverSource Wealth Advisors LLC now owns 808 shares of the specialty chemicals company’s stock valued at $74,000 after acquiring an additional 219 shares in the last quarter. GAMMA Investing LLC lifted its stake in Cabot by 10.7% in the fourth quarter. GAMMA Investing LLC now owns 1,348 shares of the specialty chemicals company’s stock valued at $123,000 after acquiring an additional 130 shares during the last quarter. Manchester Capital Management LLC grew its position in Cabot by 1,685.1% in the fourth quarter. Manchester Capital Management LLC now owns 1,678 shares of the specialty chemicals company’s stock worth $153,000 after acquiring an additional 1,584 shares in the last quarter. Finally, Coldstream Capital Management Inc. acquired a new position in shares of Cabot during the 3rd quarter worth $226,000. Hedge funds and other institutional investors own 93.18% of the company’s stock.

About Cabot

Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.